Menu Search
Equities

Mithra Pharmaceuticals SA

1TM:FRA

Mithra Pharmaceuticals SA

Actions
  • Price (EUR)0.1756
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-92.28%
  • Beta--
Data delayed at least 15 minutes, as of Apr 29 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mithra Pharmaceuticals SA is a Belgian-based company active in the pharmaceutical industry. The Company is a biotech company providing solutions in a field of women’s health, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span. The Company provides three development candidates built on Mithra’s estrogen platform, Estetrol (E4): Estelle, a solution for oral contraception, PeriNesta, the oral treatment targeting perimenopause and Donesta, a hormone therapy. The Company also develops and manufactures therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. The Company operates in more than 100 countries around the world and is headquartered in Liege, Belgium.

  • Revenue in EUR (TTM)40.16m
  • Net income in EUR-173.50m
  • Incorporated1999
  • Employees229.00
  • Location
    Mithra Pharmaceuticals SARue de l'Expansion 57FLEMALLE 4400BelgiumBEL
  • Phone+32 43533700
  • Fax+32 43492821
  • Websitehttps://www.mithracdmo.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.